Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna, Inc. : The underlying trend is to the upside

share with twitter share with LinkedIn share with facebook
share via e-mail
05/20/2020 | 09:42am EDT
long trade on a pullback
Stop-loss triggered
Entry price : 68$ | Target : 99.7$ | Stop-loss : 59.7$ | Cancellation Level : 87$ | Potential : 46.62%
The current trading zone is interesting to the point that investors should pay attention to the stock and anticipate a return of the underlying upward trend.
Investors should buy the stock at current prices near $ 68 in order to target the $ 99.7.
Moderna, Inc. : Moderna, Inc. : The underlying trend is to the upside
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The stock is in a well-established, long-term rising trend above the technical support level at 29.61 USD

Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 87.63.
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
  • Low profitability weakens the company.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Based on current prices, the company has particularly high valuation levels.

David Meurisse
© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 97,1 M - -
Net income 2020 -516 M - -
Net cash 2020 1 752 M - -
P/E ratio 2020 -43,2x
Yield 2020 -
Capitalization 23 913 M 23 913 M -
EV / Sales 2019
EV / Sales 2020 228x
Nbr of Employees 850
Free-Float 79,7%
Upcoming event on MODERNA, INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 85,42 $
Last Close Price 61,50 $
Spread / Highest target 82,1%
Spread / Average Target 38,9%
Spread / Lowest Target -15,4%
EPS Revisions
Managers
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
Lorence H. Kim Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.214.42%23 913
LONZA GROUP33.49%36 433
IQVIA HOLDINGS INC.-3.23%28 553
SEATTLE GENETICS, INC.37.59%27 213
CELLTRION, INC.17.96%23 085
INCYTE CORPORATION16.71%22 153